The Sindh Blood Transfusion Authority authorized the Dow university to collect plasma for immunoglobulin production (IVIG or intravenous injection), while the National Bio-Ethics Committee also approved the study earlier this month.
In early April, dow university experts prepared intravenous immunoglobulin for corona treatment, according to a university statement.
This treatment makes immunoglobulins transparent by separating the antibodies that grow in the blood from a patient recovering from the corona virus infections.
This treatment is very different from plasma treatment, but this immunoglobulin is removed from the plasma.
According to Professor Shaukat Ali, leader of the research team, large amounts of plasma are required to produce immunoglobulins. To this end, the Sindh Blood Transfusion Authority has been asked for permission to collect plasma obtained during drug regulation.
The agency also approved the pharmacological study (by intravenous injection) late last month.
It should be noted that this treatment is very effective against the FDA-approved safe Lorsk and Corona.
The Dow University team initially managed to take blood samples in March 2020 and then chemically isolated the antibodies, purified them and later concentrated them using ultrafiltration techniques.
In this procedure, the residual unwanted substances from antibodies, including some viruses and bacteria, are deposited to form the final product, hyperimmunoglobulin.
Also Read: DOW UNIVERSITY CLAIMED THE OUTBREAK IN CORONA TREATMENT
It is noteworthy that this immunoglobulin was first produced in the world from the blood of a patient recovered from Corona in Pakistan.
According to Prof. Shaukat Ali, this method is a type of immobile immunization (peso immunization), but instead of using all the plasma, it is transparent and only antibodies are ingested.
This safe and effective method has been widely used before. It has been used effectively in the global epidemic of storks, measles and mumps, and transparent antibodies to tetanus, influenza and rabies are also commercially available worldwide.
The research team isolated antibodies that had rendered Corona ineffective by laboratory testing and hyperimmunoglobulins to remove small amounts of blood from healthy Covod 19 patients from animal studies.
However, successfully stored in experimental vials, large plasma donations are required to produce large area injections.
Professor Muhammad Saeed Qureshi, director of Daewoo University, congratulated the research team on the permission of the Sindh Blood Transfusion Authority to collect plasma and instructed them to work hard, honestly and sincerely to produce this immunoglobulin.
In earlier Dr Tahir shamsi told about this treatment in a Geo TV program
Dr #Tahir #Shamsi told about the Coronavirus treatment by #immunoglobulin pic.twitter.com/exigOP4t9g
— LIFEINPAKISTAN (@LIFEINPAKISTAN1) May 7, 2020
